LATEST UPDATES » Vol 24, No. 11, November 2020 – Genetic Studies for Diabetes in Asia: The Key to Precision Medicine       » New Leukaemia Vaccine Developed       » Virus-Free Plants, A Mystery Solved       » New Research Methodology for identifying SARS-CoV-2       » New Hope for Detecting Early Stage Pulmonary Hypertension       » Singapore Company Homage Launches Teleconsultation and Mobile Medicine Programme      
Vol 24, No. 11, November 2020   |   Issue PDF view/purchase
Patent Granted for Automated Heart Ultrasound Analysis Workflow
Formerly known as eko.ai, the newly rebranded Us2.ai has gained patent licencing for its automated clinical workflow for heart ultrasound analysis. Working in collaboration with Janssen and AstraZeneca, to automate the fight against cardiovascular disease.

Heart failure is a global health problem, affecting more than 64 million people worldwide. In developed countries, the prevalence of diagnosed heart failure is estimated at one to two percent of the adult population, with the true prevalence including unrecognized heart failure even higher. Echocardiography is a cardiologist’s top tool of choice to safely image the heart, and the key diagnostic test required for the diagnosis of heart failure. However, conventional echocardiography is time consuming, expensive and only undertaken by highly trained specialists.

Sequoia India and EDBI backed start-up, eko.ai, announced on World Heart Day 2020 several significant achievements, including the renaming of the company to Us2.ai. The MedTech start-up is leveraging on machine learning to automate the analysis of echocardiograms or ultrasound images of the heart.

Us2.ai was also pleased to announce the grant of a U.S. Patent No. 10,702,247 for its automated clinical workflow that recognizes and analyses 2-dimensional and Doppler echo images for cardiac measurements and the diagnosis, prediction and prognosis of heart disease.

"Us2 software transforms what today is a slow, manual and error prone process into less than two minutes, one click and zero variability, delivering a complete echo report,” said James Hare, CEO and co-founder of Us2.ai.

“The potential of our AI platform has led to multiple research collaborations, and we’re delighted to welcome both AstraZeneca and Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, as strategic partners in our mission to automate the fight against cardiovascular disease.”

The collaboration with Janssen will focus on automating echocardiography analyses to facilitate identification of pulmonary hypertension. The AstraZeneca research collaboration will refine algorithms for the diagnosis of heart failure, as well as test access to automated echocardiogram analysis with point-of-care solutions for people with heart failure.

“Since our founding three years ago, we’ve been driven by the conviction that AI can help broaden access to diagnosis and potentially lifesaving treatment,” said Yoran Hummel, President and co-founder of Us2.ai.

“These announcements reflect the rapid pace of our development and commitment to providing the next generation of ultrasound to us all.”


news Virtual Expo Connect to empower access for international pharma to the world’s largest pharma ingredients market
news WEIPU, AstraZeneca, Huadong Medicine, Saint-Gobain, Baxter, Wuxi AppTec, Henlius, Medtronic and more confirmed to speak at E&L China this December
news Singapore company among the ten winners of Falling Wall Breakthrough of the Year 2020, Science Start-up
news PharmaSources Launches the Export-Driven Event CPhI & P-MEC China E-Trade Season

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy